Freeline Therapeutics Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
221
- Stock Symbol
-
FRLN
- Share Price
-
$0.45
- (As of Tuesday Closing)
Freeline Therapeutics General Information
Description
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.
Contact Information
Website
www.freeline.life
Formerly Known As
Newincco 1354
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Herts
- Stevenage SG1 2FX
- England, United Kingdom
+44 01438 000000
Freeline Therapeutics Timeline
Freeline Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.45 | $0.46 | $0.39 - $1.28 | $29.8M | 65M | 95.5K | -$2.12 |
Freeline Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 12,890 | (65,465) | 527,829 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (98,912) | (138,063) | (94,555) | (52,302) |
| Net Income | (100,673) | (140,391) | (96,322) | (53,909) |
| Total Assets | 100,075 | 141,125 | 268,612 | 97,390 |
| Total Debt | 11,959 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Freeline Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Freeline Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Freeline Therapeutics Patents
Freeline Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202214328-D0 | Method | Pending | 29-Sep-2022 | ||
| GB-202205557-D0 | Detecting nucleic acid impurity | Pending | 14-Apr-2022 | ||
| GB-202205514-D0 | Mechanical lysis | Pending | 13-Apr-2022 | 0 | |
| GB-202119034-D0 | Polypeptide | Pending | 24-Dec-2021 | ||
| GB-202119033-D0 | Assay | Pending | 24-Dec-2021 |
Freeline Therapeutics Executive Team (21)
Freeline Therapeutics Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amit Nathwani | Freeline Therapeutics | Board Member & Founder | 000 0000 |
| Christopher Hollowood Ph.D | Syncona | Executive Chairman | 000 0000 |
| Colin Love | Self | Board Member | 000 0000 |
| Jeffrey Chodakewitz MD | Self | Board Member | 000 0000 |
| Julia Gregory | Self | Board Member | 000 0000 |
Freeline Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Freeline Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|